Quantitative Silencing of EGFP Reporter Gene by Self-Assembled siRNA Lipoplexes of LinOS and Cholesterol

Abdelkader A. Metwally and Ian S. Blagbrough*

Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.

Judith M. Mantell

School of Biochemistry and Wolfson Bioimaging Facility, University of Bristol, Bristol BS8 1TD, U.K.

*Corresponding author: prsisb@bath.ac.uk ResearcherID **D-9148-2011** tel: 44-1225-386795

ABSTRACT: Non-viral siRNA vectors prepared by the direct mixing of siRNA and mixtures of an asymmetric N^4,N^9-diacyl spermine conjugate, N^4-linoleoyl-N^9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS), with either cholesterol or DOPE, at various molar ratios of the neutral lipids, are reported. The effects of varying the lipid formulation and changing the N/P charge ratio on the intracellular delivery of siRNA to HeLa cells and on the siRNA-mediated gene silencing of a stably expressed reporter gene (EGFP) were evaluated. The presence of either cholesterol or DOPE in the mixture resulted in a marked increase in the delivery of the siRNA as well as enhanced EGFP silencing as evaluated by FACS. A LinOS/Chol 1:2 mixture resulted in the highest siRNA delivery and the most efficient EGFP silencing (reduced to 20%) at $N/P = 3.0$. Lowering the amount of siRNA from 15 pmol to 3.75 pmol, thus increasing the N/P charge ratio to 11.9, resulted in decreasing the amount of delivered siRNA, while the efficiency of gene silencing was comparable to that obtained with 15 pmol ($N/P = 3.0$) of siRNA. Mixtures of symmetrical N^4,N^9-dioleoyl spermine (DOS) with cholesterol at 1:2 molar ratio showed less siRNA delivery than with LinOS/Chol at $N/P = 3.0$ (15 pmol siRNA), and comparable delivery at $N/P = 11.9$ (3.75 pmol siRNA). The EGFP silencing was comparable with LinOS and with DOS when mixed with cholesterol 1:2 (lipoplexes prepared with 15 pmol siRNA), but LinOS mixtures showed better EGFP silencing when the siRNA was reduced to 3.75 pmol. Lipoplex particle size determination by DLS of cholesterol mixtures was 106-118 nm, compared to 194-356 nm for lipoplexes prepared with the spermine conjugates only, and to 685 nm for the LinOS/DOPE 1:1 mixture. Confocal microscopy showed successful siRNA delivery of red tagged siRNA and quantitative EGFP knock-down in HeLa EGFP cells; Z-stack photomicrographs showed that the delivered siRNA is distributed intracellularly. Cryo-TEM of siRNA LinOS/Chol 1:2 lipoplexes shows the formation of multilamellar spheres with a size of ~100 nm, in good agreement with the particle size measured by DLS. The constant distance between lamellar repeats is ~6 nm, with the electron-dense layers fitting a monolayer of siRNA. AlamarBlue® cell viability assay showed that the lipoplexes resulted in cell viability $\geq 81\%$, with LinOS/Chol 1:2 mixtures resulting in cell viabilities of 89% and 94% at siRNA 15 nM and 3.75 nM respectively. These results show that lipoplexes of siRNA and LinOS/Chol mixtures prepared by the direct mixing of the lipid mixture and siRNA, without any preceding pre-formulation steps, result in enhanced siRNA delivery and EGFP knock-down, with excellent cell viability. Thus, LinOS/Chol 1:2 mixture is a promising candidate as a non-toxic non-viral siRNA vector.

KEYWORDS: *cholesterol, cryo-TEM, lipoplexes, nanoparticles, polyamine, self-assembly, siRNA, spermine, Z-stack*

INTRODUCTION

Small (or short) interfering RNA (siRNA) is a double-stranded RNA (dsRNA), typically 21-25 nucleotides per strand. Sequence-specific post-transcriptional gene silencing by siRNA has many potential therapeutic applications [1] as well as being an important tool in the study of functional genomics. In 1998, Fire, Mello, and co-workers reported the reduction or inhibition (hence genetic "interference") of the expression of a specific gene in *Caenorhabditis elegans* by means of dsRNA that is homologous to 742 nucleotides in the targeted gene,[2] a discovery that was awarded the Nobel Prize in Physiology or Medicine in 2006. In 2001, Elbashir et al. reported that sequence-specific gene silencing with 21 nucleotide siRNA occurs in mammalian cell cultures.[3] The optimum length of siRNA to affect sequence specific gene silencing in mammalian cells is typically less than 30 nucleotides in each strand of the dsRNA. Such a length does not induce interferon synthesis that leads to non-specific mRNA degradation, but it maintains mRNA sequence-specific degradation.[3] The core complex for mRNA degradation is the RNA induced silencing complex (RISC), a complex of proteins and the siRNA that have a complementary sequence to the targeted mRNA. The key proteins in the degradation process belong to the argonaute family of proteins which contain a domain with RNase H (endonuclease) type activity that catalyses cleavage of the phosphodiester bonds of the targeted mRNA. The assembly of RISC and its subsequent function to mediate sequence-specific mRNA degradation occur in the cytoplasm.[4]

Gene silencing mediated by siRNA requires that the siRNA is protected from various exo- and endo-nucleases [5] and is delivered intact to cytoplasm of the target cell.[6] The negative charges of the siRNA phosphate backbone must be masked to facilitate the siRNA-vector complex (lipoplex) binding to the cell membrane which is then followed by cellular entry of the lipoplex mainly via endocytosis and to a lesser extent by membrane fusion.[7] Thus, a vector is needed to fulfil these requirements. Non-viral vectors used for gene delivery (DNA based) and gene silencing by siRNA or shRNA include lipid-based vectors, polymer-based vectors e.g. polyethylenimine, carbohydrate-based polymers e.g. cyclodextrin and chitosan, dendrimers e.g. polyamidoamine [8] and polypropylenimine, and polypeptides.[9-12] Lipid-based non-viral vectors are widely used for siRNA delivery.[13-15] We have previously designed, synthesized, and characterized fatty acid derivatives of the naturally occurring polyamine spermine, and tested their ability to deliver siRNA to cells in vitro [16-18] and to mediate siRNA dependent gene silencing.[19, 20]

In this work, we report the formulations of a new spermine diacyl fatty acid derivative N^4-linoleoyl-N^9-oleoyl-1,12-diamino-4,9-diazadodecane characterized in preparing self-assembled lipoplexes with siRNA either on its own without a helper lipid, or in co-formulae with cholesterol or DOPE, and without pre-formulation of liposomes. The prepared lipoplexes were evaluated for their efficiency in delivering siRNA, in mediating gene-silencing, and for their effects on cell viability.

3

MATERIALS AND METHODS

Materials and general methods. Chemicals were purchased from Sigma-Aldrich (Gillingham, UK) and solvents were purchased from Fisher Scientific UK (Loughborough, UK). AlamarBlue® and cell culture media were purchased from Gibco (Invitrogen Ltd, Paisley, UK). HeLa cells stably expressing EGFP were obtained from the Cell Service at Cancer Research UK (CRUK, London Research Institute, Clare Hall Laboratories, South Mimms, London, UK). The high resolution (HR) time-of-flight mass spectra were obtained on a Bruker Daltonics micrOTOF mass spectrometer using electrospray ionisation (ESI). AllStars negative control siRNA (siNC) and it tagged with Alexa Fluor® 647 (siNC-AF) at the 3'-position were purchased from Qiagen (Crawley, UK) as was siRNA against EGFP labelled with Alexa Fluor® 647 (siEGFP-AF) at the 3'-position of the sense strand, sequences:

Sense strand: 5'-GCAAGCUGACCCUGAAGUUCAUTT-3',

Anti-sense strand: 5'-AUGAACUUCAGGGUCAGCUUGCCG-3',

Target DNA sequence: 5'-CGGCAAGCTGACCCTGAAGTTCAT-3'.

N^4-*Linoleoyl-N^9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) and N^4,N^9-dioleoyl-1,12-diamino-4,9-diazadodecane (DOS)*. We confirmed the authenticity of N^4-linoleoyl-N^9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) (HRMS, found (M+H)$^+$ 729.6980, $C_{46}H_{89}N_4O_2$ requires (M+H)$^+$ 729.6986) and N^4,N^9-dioleoyl-1,12-diamino-4,9-diazadodecane (DOS) (HRMS, found (M+H)$^+$ 731.7162, $C_{46}H_{91}N_4O_2$ requires (M+H)$^+$ 731.7137) by the HRMS of homogenous samples.[20-25]

siRNA lipoplex preparation. LinOS, DOS, cholesterol, and DOPE were prepared as ethanolic solutions. For LinOS and DOS mixtures with cholesterol and DOPE, the required volumes of the ethanolic solutions of the single lipids were mixed together. To prepare the lipoplexes, two working liquids A and B were prepared. Liquid A was prepared by adding the required amount of siRNA (siEGFP-AF, siNC-AF, or siNC) to OptiMEM I media, such that the concentration of siRNA was adjusted to 1 pmol/1 µL. Liquid B was prepared by adding the required volume of lipid ethanolic solution to OptiMEM I media, such that the final concentration of LinOS or DOS was 0.75 µg/µL followed by mixing on a vortex mixer for 3 s. Liquid A was added to liquid B and they were mixed by vortex mixer for 3 s. The lipoplex preparation was then simply allowed to stand for 20 min at 20 °C to allow lipoplex formation by charge neutralization and equilibration. TransIT-TKO was prepared according to the supplier's (Mirus) instructions.

Particle size and zeta potential measurements. Lipoplexes were prepared by adding siRNA solution (75 µL, 1 µM) in HEPES (pH 7.4, 10 mM) to HEPES (250 µL) containing the specified amount of cationic lipid transfection reagent followed by vortex mixing for 3 s. After 20 min, samples were diluted to a final volume of 3 mL with HEPES buffer and shaken gently for 10 s

directly before measurement. Measurements were carried out using Malvern Zetasizer Nano S90 with refractive index 1.59, viscosity 0.89 cP, dielectric constant 79, temperature 25 °C, and with equilibrium time 3 min. Z-Average diameter (nm) and zeta potential (mV) were recorded as averages of three and six measurements respectively.

Transfection studies of HeLa cells stably expressing EGFP. Cells were trypsinized at confluency of 80-90% and were seeded at a density of 65,000 cells/well in 24-well plates. They were incubated for 24 h at 37 °C, 5% CO_2, prior to transfection. On the day of transfection, the lipoplex solutions were added to wells containing DMEM (10% FCS) to make the final volume in each well 1 mL and final siRNA concentration 15 nM. The plates were then incubated for 48 h at 37 °C, 5% CO_2. The *N/P* charge ratio is calculated as:

$$N/P = \frac{number\ of\ moles\ of\ cationic\ lipid \times 2}{number\ of\ moles\ of\ siRNA \times number\ of\ bases\ in\ each\ siRNA\ strand \times 2}$$

Flow cytometry (FACS). For analysis of delivery and then reduction of expression of EGFP by flow cytometry (FACS), cells were trypsinized, resuspended in complete DMEM medium without phenol red. Cells were centrifuged (1,000 rpm for 5 min) and washed twice by resuspending in PBS containing 0.1% BSA then re-centrifuged (1,000 rpm for 5 min). The collected cells was then resuspended in PBS and transferred to a flow cytometer tube (Becton Dickinson, UK). Cells were analyzed (10,000 or 20,000 events) using a FACSCanto flow cytometer (Becton Dickinson, UK), equipped with an argon ion laser at 488 nm for excitation, a Long Pass (LP) filter at 502 nm and a detector at 530 nm (range +/-15 nm) for fluorescence emission, helium/neon laser at 633nm, and detector for the Alexa Fluor 647 at 660 nm (range +/- 10 nm). EGFP expression is calculated as:

$$\%EGFP = \frac{EGFP\ fluorescence\ of\ transfected\ cells}{EGFP\ fluorescence\ of\ control\ cells} \times 100$$

siRNA delivery was evaluated 48 h post-transfection by means of normalizing the geometric mean fluorescence of the Alexa Fluor 647 of each sample relative to the geometric mean fluorescence of Alexa Fluor 647-siRNA delivered by either of two standards, DOS or TransIT-TKO.

Confocal microscopy cell imaging. Cells were trypsinized at confluency of 80-90% and were seeded at a density of 65,000 cells/well in 24-well plates that have a round-glass cover slip (12 mm diameter) and were incubated for 24 h prior to transfection which was carried out as described above. After 48 h, the cell culture media were aspirated from each well, and the cells were washed with PBS (3 x 0.5 mL). The cell membrane was then stained with wheat germ agglutinin (WGA) conjugated to Alexa Fluor® 555. The concentration of WGA-Alexa Fluor® 555 working solution was 5 µg/mL in Hank's balanced salt solution without phenol red. The cells were incubated for 10 min in the dye working solution at 37 °C, 5% CO_2 in the dark. The cells were washed with PBS (3 x 0.5 mL) and

then fixed with 4% paraformaldehyde in PBS solution for 20 min at 20 °C in the dark. The cover slips were then removed from each well, left to dry briefly in air, and then mounted on glass slides using Mowiol (polyvinyl alcohol from Calbiochem, Nottingham, UK) solution as the mounting media and left in the dark at 20 °C (18 h) to allow hardening of the mounting media. The cells were examined using a Carl Zeiss laser scanning microscope LSM 510 meta, with EGFP excitation 488 nm, emission 505-550 nm (band pass filter), Alexa Fluor® 555 excitation 543 nm, emission 560-615 nm (band pass filter), and Alexa Fluor® 647 excitation 633 nm, emission 657-753 nm (meta detector).

Cryo-transmission electron microscopy (Cryo-TEM). siNC lipoplexes were prepared with LinOS/Chol 1:2 (0.75 µg LinOS per 3.75 pmol siNC, $N/P = 11.9$) in 10 mM HEPES buffer. A sample (5 µL) was pipetted onto a previously glow discharged, lacy carbon-coated copper grid (Electron Microscopy Services). The excess was then blotted and the sample plunge frozen into liquid ethane using a Vitrobot plunge freezer (FEI Company). The sample was transferred to a Gatan 626 Cryotransfer holder and the lipoplexes were examined at a temperature of approximately −170 °C in an FEI Tecnai 20 Transmission Electron Microscope operating at 200kV.

Cell viability assay. HeLa cells were trypsinized at confluency of 80-90% and seeded at a density of 6,500 cells/well of 96-well plates. The transfection was carried out using the same protocol as transfecting the 24-well plates, as described above, with the exception of reducing the amount of siNC lipoplexes such that each well typically contains 1.5 pmol siNC in a final volume of 100 µL/well (15 nM) of DMEM containing 10% FCS. Also, the cell viability of LinOS/Chol (1:2) 3.75 was measured at only 0.375 pmol siNC/well (3.75 nM). After incubation for 44 h at 37 °C in 5% CO_2, alamarBlue (10 µL) was added to each well. After incubation for 3.5 h at 37 °C in 5% CO_2, the absorbance of each well was measured at 570 nm and 600 nm using a microplate-reader (VERSAmax), and the amount of reduced alamarBlue at 570 nm calculated as:

$$Amount\ reduced = A_{570} - (A_{600} \times R), \quad R = \frac{AOx_{570}}{AOx_{600}}, \quad \text{correction factor without cells}$$

where AOx_{570} and AOx_{600} are the absorbance of oxidized alamarBlue at 570 and 600 nm respectively.

Percentage viability is calculated as:

$$\% \ viability = \frac{amount\ of\ reduced\ alamarBlue\ of\ sample\ cells}{amount\ of\ reduced\ alamarBlue\ of\ control\ cells} \times 100$$

Statistical analysis. All data are presented as mean + S.D. ($n = 9$). The mean values and SD were determined using MS Office Excel 2003. Statistical significance of differences between data was evaluated by Student's unpaired two tailed t-test. A value of $p < 0.05$ was considered significant, and p values were determined using GraphPad.

RESULTS

(A)

(B)

(C)

(D)

Figure 1. (A) N^4-Linoleoyl-N^9-oleoyl-1,12-diazododecane (LinOS), (B) N^4,N^9-dioleoyl-1,12-diazododecane (DOS), (C) cholesterol, (D) 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE).

We will evaluate the efficiency of both siRNA delivery and gene silencing by siRNA lipoplexes prepared from LinOS (Figure 1A) or DOS (Figure 1B) co-formulated with either cholesterol (Figure 1C) or DOPE (Figure 1D) helper lipids. LinOS and DOS are derivatives of the naturally occurring polyamine, spermine, conjugated to the naturally occurring C18 unsaturated fatty acids: oleic acid (18:1) and/or linoleic acid (18:2). Cholesterol and DOPE are neutral helper lipids widely used in gene therapy as they aid membrane fusion which may be one of the mechanisms (along with endocytosis) of the functional delivery of lipoplexes.[7]

The lipid dispersions in OptiMEM I media were prepared by addition of ethanolic solutions of the single lipids (Figure 1) or lipid mixtures to OptiMEM I followed by brief mixing on a vortex mixer. This simple procedure avoids the use of sonication or extrusion techniques which are used to prepare single lamellar vesicles and/or reduce the size of the prepared lipid vesicles. Our procedure can be considered as an even more direct method than the ethanol injection vesicle protocol.[26, 27]

Figure 2 shows the effect of changing the LinOS/Chol molar ratio on the delivery of siEGFP-AF or siNC-AF in the transfected HeLa cells measured by flow cytometry (FACS). The highest siEGFP-AF delivery was achieved with lipoplexes having a LinOS/Chol ratio of 1:2, as these lipoplexes

resulted in normalized Alexa Fluor 647 (AF647) fluorescence of 250. The difference between the value obtained by lipoplexes of LinOS/Chol 1:2 and the closest value of 165 of lipoplexes of LinOS/Chol 1:3 was statistically significant ($p = 0.0005$). Decreasing the molar ratio of LinOS/Chol from 3:1 to 1:2, i.e. increasing the amount of cholesterol in the mixtures, resulted in an increase in the normalized AF647 fluorescence from 11 to 250 respectively. Co-formulation with cholesterol in the lipoplexes of LinOS/Chol 1:2 resulted in a significant increase of normalized AF647 fluorescence when compared with lipoplexes of LinOS only, from 6 with LinOS lipoplexes to 250 with LinOS/Chol 1:2 lipoplexes which means a ~42-fold increase in siEGFP-AF delivery. The cholesterol data column (Chol) shows that cholesterol alone did not result in any significant siEGFP-AF delivery. Lipoplexes of siNC-AF and LinOS/Chol 1:2 resulted in comparable delivery of siNC-AF when compared with lipoplexes of siEGFP-AF and LinOS/Chol 1:2, normalized AF fluorescence of 268 and 250 respectively ($p = 0.28$).


Figure 2. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the geometric mean fluorescence of Alexa Fluor 647 (AF647) 48 h post-transfection of HeLa cells with the lipoplexes prepared with LinOS/Chol and either siEGFP-AF at different LinOS/Chol ratios or siNC-AF at LinOS/Chol 1:2 (per each well, the amounts of LinOS, siEGFP-AF, and siNC-AF were kept constant at 0.75 μg, 15 pmol, and 15 pmol respectively, *N/P* = 3.0). The LinOS/Chol ratio is the molar ratio. Light grey columns represent lipoplexes prepared with siEGFP-AF, the black column represents lipoplexes of LinOS/Chol 1:2 with siNC-AF.

Figure 3. EGFP percentage expression calculated 48 h post-transfection of HeLa cells with the lipoplexes prepared with LinOS/Chol and either siEGFP-AF at different LinOS/Chol ratios or siNC-AF at LinOS/Chol 1:2 (per each well, the amounts of LinOS, siEGFP-AF, and siNC-AF were kept constant at 0.75 µg, 15 pmol, and 15 pmol respectively, *N/P* = 3.0). Light grey columns represent lipoplexes prepared with siEGFP-AF, the black column represents lipoplexes of LinOS/Chol 1:2 with siNC-AF.

Figure 3 shows the effect of changing the LinOS/Chol molar ratio on the percentage expression of EGFP in the transfected HeLa cells measured by FACS. The molar LinOS/Chol ratio was changed from 3:1 to 1:3. The best lipoplexes were those having LinOS/Chol ratio of 1:2, as these lipoplexes resulted in a reduction of EGFP percentage expression to 20%, which is statistically significant when compared to the reduction of EGFP obtained by lipoplexes of LinOS/Chol 1:3 (26%, *p* = 0.0024) and LinOS/Chol 1:1 (27%, *p* = 0.0001) which were the second best in terms of EGFP expression reduction. Co-formulation with cholesterol in the lipoplexes of LinOS/Chol 1:2 resulted in reducing the EGFP percentage expression from 32% for lipoplexes of LinOS only to 20% (*p* = 0.0001). The cholesterol data column shows that siEGFP-AF only formulated with cholesterol did not have any practically significant effect on EGFP expression (100% ± 5). Lipoplexes of siNC-AF and LinOS/Chol 1:2 did not result in any reduction in EGFP expression (105% ± 5). Transfection of siEGFP-AF using the commercial reagent TransIT-TKO (a proprietary formulation based on a cationic polymer formulation) under the same experimental conditions, siEGFP-AF (15 pmol)

formulated with TransIT TKO resulted in EGFP percentage of expression of 20% (Figure 3). Thus, in terms of transfection efficiency, there was no statistically significant difference between the percentage reductions of EGFP expression due to transfection with lipoplexes of LinOS/Chol 1:2 and TransIT-TKO ($p = 1.00$).

LinOS/Chol 1:2 lipoplexes with siEGFP-AF resulted in both highest siRNA delivery and most efficient reduction of EGFP (from 100% to 20%, 5-fold). The reduction of EGFP with LinOS/Chol lipoplexes having different LinOS/Chol ratios is affected by the amount of siEGFP-AF delivered. However, it can be seen that although siRNA delivery with lipoplexes of LinOS/Chol of molar ratio 1:2 and 3:1 was 250 and 11 respectively (~23-fold), the reduction of EGFP was to 20% and to 46% (~2-fold). Thus, it is difficult to predict the functional biological activity of siRNA based solely on the amount delivered. One explanation is that siRNA lipoplexes might be delivered via different cellular internalization pathways such as clathrin- or caveolin-mediated endocytosis and/or membrane fusion. A recent report showed that the functional delivery of siRNA lipoplexes is not necessarily via endocytic pathways, but rather might be due to another cellular internalization mechanism such as membrane fusion.[7] Thus, although the amounts of siRNA delivered might vary largely, the resultant reduction in EGFP may not correspond exactly with that same large variation.


Figure 4. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the geometric mean fluorescence of AF647 48 h post-transfection with the lipoplexes prepared with LinOS/DOPE (LinOS/DOPE) and siEGFP-AF at different LinOS/DOPE ratios and *N/P* = 3.0 (per each well, the amounts of LinOS and siEGFP-AF were kept constant at 0.75 µg and 15 pmol respectively). Light grey columns represent lipoplexes prepared with siEGFP-AF while the black column represents lipoplexes of LinOS/DOPE 1:1 with siNC-AF.

Figure 4 shows the effect of changing the LinOS/DOPE molar ratio from 1:3 to 3:1 on the delivery of siEGFP-AF or siNC-AF in the transfected HeLa cells. Co-formulation with DOPE in the lipoplexes of LinOS/DOPE resulted in a significant increase of normalized AF647 fluorescence when compared with lipoplexes of LinOS only, from 6 with LinOS only to 85 and 78 respectively ($p = 0.24$) for lipoplexes of LinOS/DOPE 1:3 and 1:1 which gave the highest AF647 normalized fluorescence. Lipoplexes with molar ratio of LinOS/DOPE 1:2 and 2:1 resulted in normalized AF647 fluorescence of 48 and 21 respectively ($p = 0.0001$). The DOPE data column shows that siEGFP-AF formulation with DOPE only did not result in any practically significant siEGFP-AF delivery. Lipoplexes of siNC-AF and DOPE/Chol 1:1 resulted in normalized AF647 fluorescence of 51.


Figure 5. EGFP percentage expression calculated 48 h post-transfection of HeLa cells with the lipoplexes prepared with LinOS/DOPE and siEGFP-AF at different LinOS/DOPE ratios and $N/P = 3.0$ (per each well, the amounts of LinOS and siEGFP-AF were kept constant at 0.75 µg and 15 pmol respectively). Light grey columns represent lipoplexes prepared with siEGFP-AF while the black column represents lipoplexes of LinOS/DOPE 1:1 with siNC-AF.

Figure 5 shows the effect of changing the LinOS/DOPE molar ratio on the percentage expression of EGFP in the transfected HeLa cells. The LinOS/DOPE molar ratio was changed from 1:3 to 3:1. There were very little differences between the percentage expressions of EGFP after transfection with the LinOS/DOPE lipoplexes at all LinOS/DOPE ratios, with LinOS/DOPE 1:1 lipoplexes resulting in EGFP percentage expression of 21%, and no statistically significant difference was found between any of the EGFP percentage expressions resulting from the transfection with the

11

LinOS/DOPE lipoplexes. Co-formulation with DOPE in the lipoplexes of LinOS/DOPE 1:1 resulted in reducing the EGFP percentage expression from 32% for lipoplexes of LinOS to 21% ($p = 0.0001$). DOPE column shows that formulating siEGFP-AF with DOPE only did not result in any practically significant effect on EGFP expression ($105\% \pm 3$). Lipoplexes of siNC-AF and LinOS/DOPE 1:1 did not result in any reduction in EGFP expression ($101\% \pm 3$). There was no statistically significant difference between the percentage expressions of EGFP after transfection with lipoplexes of LinOS/DOPE 1:1 and TransIT-TKO ($p = 0.49$). Although the amount of delivered siEGFP-AF increased markedly with the addition of DOPE, the differences in the delivered amount did not reflect significant differences in the reduction of EGFP corresponding to the differences in the delivered amount. For example, lipoplexes of LinOS/DOPE 1:1 and 3:1 delivered siEGFP-AF with values of 78 and 12 respectively, and reduced EGFP (from 100%) to 21% and 23% respectively. This, as discussed previously with LinOS/Chol lipoplexes, reflects the possibility of the presence of a specific functional mechanism which results in the required specific gene silencing.[7]


Figure 6. siEGFP-AF delivery to HeLa cells 48 h post-transfection with the lipoplexes prepared with LinOS/Chol 1:2 or DOS/Chol 1:2 at *N/P* = 3.0 or *N/P* = 11.9 (per each well, the amounts of LinOS and DOS were kept constant at 0.75 µg). Lipoplexes names ending in 15 and 3.75 represent lipoplexes prepared with 15 pmol and 3.75 pmol respectively of siEGFP-AF or siNC-AF. Light grey columns represent lipoplexes prepared with siEGFP-AF while black columns represent lipoplexes prepared with siNC-AF.

Figure 6 shows the effect of changing the *N/P* charge ratio from 3.0 to 11.9 by means of reducing the amount of siEGFP-AF (or siNC-AF) from 15 pmol/well of 24-well plates to 3.75 pmol/well, on the normalized AF647 fluorescence in the transfected cells. A comparison between the LinOS/Chol 1:2 lipoplexes and DOS/Chol 1:2 lipoplexes at *N/P* = 3.0 and 11.9 is also shown. The normalized AF647 fluorescence is significantly higher in case of lipoplexes prepared with 15 pmol siEGFP-AF or siNC-AF when compared to the lipoplexes prepared with 3.75 pmol siEGFP-AF or siNC-AF at *N/P* = 11.9. siEGFP-AF lipoplexes LinOS/Chol 15 and LinOS/Chol 3.75 resulted in AF647 normalized fluorescence of 250 and 41 respectively and $p = 0.0001$, siNC-AF lipoplexes LinOS/Chol 15 and LinOS/Chol 3.75 resulted in AF647 normalized fluorescence of 151 and 23 respectively and $p = 0.0001$. siEGFP-AF lipoplexes of DOS/Chol 15 and DOS/Chol 3.75 resulted in AF647 normalized fluorescence of 144 and 48 respectively and $p = 0.0001$, siNC-AF lipoplexes of DOS/Chol 15 and DOS/Chol 3.75 resulted in AF647 normalized fluorescence of 106 and 32 respectively and $p = 0.0001$. Lipoplexes of LinOS/Chol 15 showed the highest AF647 normalized fluorescence. AF647 normalized fluorescence resulting from transfecting HeLa cells with lipoplexes co-formulated with cholesterol were significantly higher then the fluorescence resulting from transfection with DOS or LinOS lipoplexes (DOS 15, DOS 3.75, LinOS 15, and LinOS 3.75, the four columns on the right) with siEGFP-AF.


Figure 7. EGFP percentage expression 48 h post-transfection with lipoplexes prepared with LinOS/Chol 1:2 or DOS/Chol 1:2 at *N/P* = 3.0 or *N/P* = 11.9 (per well, the amounts of LinOS and DOS were kept constant at 0.75 µg). Lipoplex names followed by 15 and 3.75 represent lipoplexes prepared with 15 pmol and 3.75 pmol respectively of siEGFP-AF or siNC-AF. Light grey columns represent lipoplexes prepared with siEGFP-AF, black columns represent lipoplexes prepared with siNC-AF.

Figure 7 shows the effect of changing the *N/P* charge ratio from 3.0 to 11.9, by means of reducing the amount of siEGFP-AF (or siNC-AF) from 15 pmol/well of 24-well plates to 3.75 pmol/well, on the percentage of EGFP expression in the transfected HeLa cells. Also shown in Figure 7 is a comparison between the LinOS/Chol 1:2 lipoplexes and DOS/Chol 1:2 lipoplexes at *N/P* = 3.0 and 11.9. HeLa cells transfected with lipoplexes of siEGFP-AF and LinOS/Chol 1:2 did not show a significant decrease in the efficiency of transfection, on decreasing the amount of siEGFP-AF from 15 pmol/well to 3.75 pmol/well. Lipoplexes of LinOS/Chol 15 and LinOS/Chol 3.75 resulted in EGFP percentage expression of 20% and 21% respectively (*p* = 0.42). Lipoplexes of DOS/Chol 1:2 showed a significant change (*p* < 0.01) of EGFP percentage expression from 21% in the case of DOS/Chol 15 to 28% in the case of DOS/Chol 3.75 lipoplexes (with siEGFP-AF 15 pmol and 3.75 pmol respectively). There were no statistically significant differences between the EGFP percentage expression due to transfection with lipoplexes of siEGFP-AF with either DOS/Chol 15 or LinOS/Chol 15 (21% and 20% respectively, *p* = 0.42). However, transfection with lipoplexes of LinOS/Chol 3.75 resulted in lower EGFP percentage expression (21%) compared to lipoplexes of DOS/Chol 3.75 (28%), *p* = 0.0001 and thus we determined experimentally that the lipoplexes of LinOS/Chol 3.75 are superior to the lipoplexes of DOS/Chol 3.75 (Figure 7). Transfection with lipoplexes of siNC-AF (15 pmol or 3.75 pmol) with DOS/Chol 1:2 or LinOS/Chol 1:2 did not result in any significant reduction of EGFP expression. Co-formulation of DOS or LinOS with cholesterol reduced the EGFP percentage expression significantly. The EGFP percentage expressions in the transfected HeLa cells for DOS/Chol 15, DOS/Chol 3.75, LinOS/Chol 15, and LinOS/Chol 3.75 were 21%, 28%, 20%, and 21% respectively, compared to DOS 15, DOS 3.75, LinOS 15, and LinOS 3.75 lipoplexes which resulted in EGFP percentage expressions of 37%, 38%, 32%, and 35% respectively. Thus there are significant improvements (*p* = 0.0001 for all four respectively) in the gene silencing on mixing with cholesterol. The amount of siEGFP-AF delivered with either DOS/Chol or LinOS/Chol lipoplexes prepared with 15 pmol siEGFP-AF was higher by ~3-fold and 5-fold respectively (Figure 6) when compared to lipoplexes prepared with 3.75 pmol siEGFP-AF. The reduction in EGFP expression by the DOS/Chol or LinOS/Chol lipoplexes prepared with either 15 pmol or 3.75 pmol only varied slightly as discussed above (Figure 7).

In Figure 7, the gene silencing of DOS/Chol 1:2 and LinOS/Chol 1:2 with 15 pmol and 3.75 pmol siEGFP-AF was efficient regardless of the difference in siEGFP-AF delivery (Figure 6) which can be explained on the basis of the actual functional mechanism of siEGFP delivery (e.g. an endocytotic mechanism vs. membrane fusion) and which in turn determines the actual functional fraction of the delivered siEGFP-AF.[7] Also, the gene silencing values shown in Figure 7 are close to the maximum reduction in EGFP expression possible after 48 h transfection, based on the ~24 h half-life of EGFP. Thus, quantitative silencing of EGFP reporter gene has been achieved by self-assembled siRNA lipoplexes of LinOS and cholesterol. LinOS/Chol 1:2 mixture resulted in the highest siRNA delivery

and the most efficient EGFP silencing (reduced to 20% i.e. quantitative after ~two half-lives) at N/P = 3.0. The efficiency of EGFP gene silencing was comparable on lowering the amount of siRNA from 15 pmol to 3.75 pmol. The 3.75 pmol siEGFP-AF payload was chosen specifically to evaluate the effect of increasing the N/P ratio while reducing the payload of siEGFP-AF without changing the amount of cationic lipid. The siEGFP-AF payload was not further reduced below 3.75 pmol because it would have resulted in an exceptionally high N/P ratio possibly with accompanying negative effects on cell viability.

The cationic lipid/helper lipid ratios which resulted in the best reduction in EGFP expression post-transfection with siEGFP-AF lipoplexes were selected (Figures 3, 5, and 6) for physicochemical analysis (Table 1). Lipoplexes were prepared with either 15 pmol siNC (N/P = 3.0) or 3.75 pmol siNC (N/P = 11.9) except for LinOS/DOPE which was prepared with 15 pmol siNC only (N/P = 3.0). Self-assembled lipoplexes of siRNA and cholesterol co-formulations with DOS or LinOS resulted in particle size (measured by DLS) in the range of 106-127 nm (Table 1). There was a slight increase in particle size in lipoplexes of DOS/Chol 1:2 from 106 nm to 127 nm upon decreasing the amount of siRNA from 15 pmol to 3.75 pmol (increasing N/P charge ratio from 3.0 to 11.9), p = 0.03. There was no statistically significant difference between the particle sizes of lipoplexes of LinOS/Chol 1:2 with either 15 or 3.75 pmol (p = 0.41). The type of cationic lipid used (DOS or LinOS) in the cholesterol mixtures did not have a significant effect on the resulting particle size at the same N/P charge ratio (same amount of siRNA), where DOS/Chol and LinOS/Chol lipoplexes at N/P = 3.0 (15 pmol siRNA) resulted in particle size of 106 and 113 respectively (p = 0.47), and DOS/Chol and LinOS/Chol lipoplexes at N/P = 11.9 (3.75 pmol siRNA) resulted in particle size of 127 and 118 respectively (p = 0.05). Lipoplexes prepared with siRNA and either DOS or LinOS, without any helper lipid, have a particle size in the range of 192-356 nm. There was a statistically significant difference between the DOS and the LinOS lipoplex particle sizes (356 and 294 respectively, p = 0.007) at N/P = 3.0 (15 pmol siRNA). At N/P = 11.9, the type of cationic lipid did not affect the particle size, with lipoplexes of DOS and LinOS having particle sizes of 192 and 194 respectively (p = 0.72). Increasing the N/P charge ratio to 11.9 (lowering the siRNA amount from 15 to 3.75 pmol) reduced the lipoplexes particle size from 356 to 192 nm (DOS, p = 0.0001) and 294 to 194 nm (LinOS, p = 0.0001). Co-formulation with cholesterol resulted in significant reduction of the prepared lipoplexes, when comparing the lipoplexes of each cationic lipid with or without cholesterol. The particle sizes of DOS/Chol 15, DOS/Chol 3.75, LinOS/Chol 15 , LinOS/Chol 3.75 (106, 127, 113, and 118 nm respectively) are significantly reduced compared to DOS 15, DOS 3.75, LinOS 15, and LinOS 3.75 (356 nm; p = 0.0001, 192 nm; p = 0.0001, 294 nm; p = 0.0001, and 194 nm; p = 0.0001 respectively). The lipoplexes of LinOS/DOPE 1:1 and 15 pmol siRNA (N/P =3.0) had the relatively larger particle size of 685 nm compared to the other lipoplex formulations.

Table 1. **Effect of formulation on the particle size and ζ-potential of lipoplexes of LinOS, DOS, DOS/Chol, LinOS/Chol, and LinOS/DOPE mixtures.**

lipoplex formulation	particle size (nm) mean ± S.D.	PDI mean ± S.D.	ζ-potential (+mV) mean ± S.D.
DOS/Chol 1:2 15 pmol siNC	106 ± 19	0.35 ± 0.04	58 ± 4
DOS/Chol 1:2 3.75 pmol siNC	127 ± 8	0.37 ± 0.02	60 ± 5
LinOS/Chol 1:2 15 pmol siNC	113 ± 13	0.34 ± 0.05	60 ± 4
LinOS/Chol 1:2 3.75 pmol siNC	118 ± 6	0.35 ± 0.06	56 ± 1
DOS 15 pmol siNC	356 ± 37	0.48 ± 0.06	56 ± 2
DOS 3.75 pmol siNC	192 ± 10	0.32 ± 0.05	52 ± 4
LinOS 15 pmol siNC	294 ± 25	0.41 ± 0.06	53 ± 3
LinOS 3.75 pmol siNC	194 ± 9	0.33 ± 0.04	60 ± 3
LinOS/DOPE 1:1 15 pmol siNC	685 ± 83	0.66 ± 0.08	64 ± 4

The ζ-potentials of the prepared lipoplexes are all positive and lie in the range 53-64 mV (Table 1). There was no significant effect of the co-formulation with cholesterol on the ζ-potentials of their prepared lipoplexes compared to the lipoplexes of their cationic lipids without cholesterol. The presence of DOPE caused no or only a very slight increase in the lipoplex ζ-potential (+64 mV) when compared to the other lipoplexes prepared with the same amount of siRNA (15 pmol) and at the same *N/P* = 3.0.

Lipoplex size is an important factor in transfection efficiency though it is not the only determinant factor.[28] Cationic cholesterol derivatized liposomes complexed with siRNA have a size range of 150-500 nm,[29] where selected siRNA lipoplexes were used either to deliver fluorescently tagged scrambled siRNA to different cell lines including HeLa cells, or to deliver siRNA silencing GFP in a T293 cell line that stably expresses GFP. Lipoplex size affects the main route of cellular entry where smaller lipoplexes (diameter < 300 nm) are likely to enter by clathrin-mediated endocytosis, while larger particles (diameter > 500 nm) enter cells by caveoli-mediated endocytosis.[30, 31] Also, the entry route that results in functional siRNA mediated gene knock-down might be by fusion with the plasma membrane rather than the endocytosis pathway.[7] The functional delivery of lipoplexes of oligonucleotides in two cell lines, including a HeLa S3 cell line, was recently reported to be by membrane fusion.[32] The authors concluded that lipoplexes internalized in cells by direct membrane fusion improve the functional delivery of oligonucleotide cargoes because they might avoid the endosomal escape step which is the rate-limiting step for many pDNA and

siRNA delivery vectors. However, the lipoplex size used in that study was 869 nm measured in OptiMEM I medium.[32]

Shown in Figure 8 are monomodal populations of LinOS/Chol 1:2 and LinOS (only) lipoplexes. The polydispersity indices (PDI) of the lipoplexes (Table 1) prepared with LinOS or DOS cholesterol mixtures were 0.35-0.37. There was no effect of changing the siRNA amount in the LinOS/Chol or DOS/Chol lipoplexes on the PDI. The PDI of lipoplexes prepared with the cationic lipids only varied from 0.32–0.48. Decreasing the amount of siRNA (thus increasing *N/P* from 3.0 to 11.9) in LinOS or DOS lipoplexes resulted in a decrease in the PDI from 0.48 to 0.32 and 0.41 to 0.33 respectively (*p* = 0.02 and 0.0005). The lipoplexes of LinOS/DOPE 1:1 resulted in a higher PDI of 0.66.

(A)

(B)

17

Figure 8. (A) Particle size distribution (DLS) for LinOS/Chol 1:2 lipoplexes prepared with 3.75 pmol siNC (*N/P* = 11.9). The hydrodynamic diameter is 117 nm and polydispersity index (PDI) = 0.31 for the shown lipoplexes. (B) Particle size distribution (DLS) for LinOS (only) lipoplexes prepared with 3.75 pmol siNC (*N/P* = 11.9). The hydrodynamic diameter is 187 nm and PDI = 0.38 for the shown lipoplexes.


(A)   (B)   (C)

(D)   (E)

Figure 9. Confocal photomicrographs. EGFP fluorescence (green), cell membrane stained with WGA-Alexa Fluor® 555 (blue), and Alexa Fluor® 647 (red) which shows tagged siEGFP-AF delivery. (A) Control non-transfected HeLa cells, (B) HeLa cells 48 h post-transfection with lipoplexes of LinOS/Chol 1:2 and siEGFP-AF (3.75 pmol), (C) as (B) with the red channel only turned on for better visualization of the delivered siEGFP-AF, (D) and (E) magnified HeLa cells 48 h post-transfection, as in (B) and (C) respectively.

Confocal photomicrographs in Figure 9 show: Figure 9A control non-transfected HeLa cells which stably express EGFP (green) contained within the cell membrane (blue). Figure 9B (63x objective, scan zoom 1.0) and Figure 9C post-transfection (48 h) with siEGFP-AF, the EGFP expression faded as the gene expression was silenced with the delivery of the siEGFP-AF (red). Figure 9D (63x objective, scan zoom 1.7) and Figure 9E magnified images which show the reduction

of EGFP expression compared to control cells, with the red colour of delivered siEGFP-AF. The images in Figure 9 prove that siEGFP-AF was delivered to the EGFP-stably transfected HeLa cells, and also that EGFP gene expression was silenced. This delivery was confirmed by taking a Z-stack of images through the thickness of the cells (Figure 10). Confocal microscopy showed successful delivery of red tagged siRNA and quantitative EGFP knock-down in these EGFP HeLa cells.


Figure 10. Z-Stack confocal photomicrographs. EGFP fluorescence (green), cell membrane stained with WGA-Alexa Fluor® 555 (blue), and Alexa Fluor® 647 (red) represents tagged siRNA delivery. A Z-stack series of photomicrographs representing 20 Z-sections in HeLa cells transfected with lipoplexes of LinOS/Chol 1:2 and siEGFP-AF (3.75 pmol).

Z-Stacks are a series of successive optical sections acquired at different positions across the Z-axis defining the thickness of the sample perpendicular to the sample's horizontal XY plane and

therefore they are useful for visualizing three-dimensional structures. To characterize the intracellular delivery of siEGFP-AF further, Z-stack photomicrographs were recorded through a monolayer of transfected HeLa cells (Figure 10). In order to record such a stack, the experiment was set up such that the first optical section was recorded slightly lower than the surface of the cells attached to the cover slip, then the sections were recorded while slicing through to the opposite surface. This arrangement allows us to identify whether the red colour (representing siRNA delivery) is present inside the cell, where there will be no blue colour (representing cell membrane) associated with the red colour, or the red colour is present on/in the cell membrane, in this case the red colour will be present simultaneously with the blue colour of the cell membrane. It can be seen in the series of Z-stack photomicrographs starting from the top left (Figure 10), that the red colour appears in the centre of the cells, the blue colour is present only in the perimeter of the cells, and there is no simultaneous blue colour in the middle of the cells where there is red. Thus, we conclude that the majority of the delivered siRNA is present inside the HeLa cells. Minko and co-workers have recently reported the use of Z-stack photomicrographs to determine the orientation of the delivered siRNA, where a NuLight DY-547 fluorophore tagged siRNA was delivered to A2780 human ovarian cancer cells by surface neutral, but internally cationic polyamidoamine dendrimers.[8]


Figure 11. Cryo-TEM image of LinOS/Chol (1:2) siRNA lipoplexes.

Lipoplexes prepared with LinOS/Chol 1:2 and siRNA form spherical multilamellar arrangements (Figure 11) with a size of ~100 nm which is in good agreement with the particle size measured by DLS (Table 1) of the same lipoplexes. The constant distance between lamellar repeats is ~6 nm, with the electron-dense layers fitting a monolayer of siRNA. Recent cryo-TEM images of lipidic aminoglycoside derivatives/siRNA self-assembled lamellar complexes show concentric onion-like structures with the distance between the lamellar repeats being 7 nm.[33] Such siRNA lipoplexes promote efficient siRNA delivery and RNA interference.

20

Figure 12. Viability of transfected HeLa cells measured using the alamarBlue assay 48 h post-transfection with lipoplexes prepared with siNC and either LinOS/Chol or LinOS/DOPE at different LinOS/neutral lipid ratios. All were assayed at 1.5 pmol siNC/well (15 nM), 6,500 cells/well, except LinOS/Chol 1:2 3.75 which had only 0.375 pmol siNC/well (3.75 nM).

Transfection of HeLa cells with lipoplexes of LinOS/Chol and LinOS/DOPE at different molar ratios and 1.5 pmol siRNA in 96-well plates (Figure 12), $N/P = 3.0$, resulted in cell viabilities of 81-95% of the control cells. The viability resulting from transfection using LinOS (only) lipoplexes was 96% at $N/P = 3.0$. Transfection with LinOS/Chol 1:2 3.75 resulted in viability of 94%, higher than that of LinOS/Chol 1:2 (89%, $p = 0.02$). These values are significantly higher than the cell viability on transfection with TransIT-TKO (82%, $p = 0.0001$ for both). There were small differences in viabilities between LinOS/Chol lipoplexes (81-95%) and LinOS/DOPE lipoplexes (84-87%). Although the amount of lipoplexes chosen in this assay was only one tenth that used in the 24-well plate assays (for delivery and gene silencing experiments), the siRNA concentration was kept constant in the culture medium in all experiments, i.e. either 15 nM or 3.75 nM.

DISCUSSION

We have evaluated the efficiency of both siRNA delivery and the gene silencing by siRNA lipoplexes prepared from mixtures of LinOS or DOS with either cholesterol or DOPE neutral helper lipids. LinOS and DOS are derivatives of a naturally occurring polyamine, spermine, that has been

conjugated to the naturally occurring C18 unsaturated fatty acids: oleic acid (18:1) and/or linoleic acid (18:2). The design of LinOS and DOS is based on the hypothesis that using such natural moieties as the building blocks in the synthetic lipid will result in more benign (less toxic) cationic lipids and that better interactions (mixing) with bilayers both without (cell membrane) and within (endosomal membrane) target cells will increase cellular delivery efficiency and endosome escape.

Cholesterol and DOPE are widely used as helper lipids in DNA liposome and lipoplex preparations,[34] mainly due to their ability to promote non-lamellar lipid arrangements and thus facilitate membrane fusion upon cellular internalization. Herein, we have demonstrated an important increase in both siRNA delivery and the resultant gene silencing efficiency with an increase in the cholesterol content in the lipoplexes (Figures 2 and 3). Cholesterol enhances transfection with DNA lipoplexes by increasing DNase resistance[35] and cholesterol nanodomains are known to form in lipoplexes having $\geq$ 52% of molar cholesterol content.[36] The presence of cholesterol domains in the lipoplexes prepared with $\geq$ 60% molar cholesterol content was suggested to result in an increasing resistance to lipoplex aggregation in the presence of 50% serum, and decreased albumin binding to the lipoplexes led to better interaction (fusion) with the cell membrane. Cholesterol and DOPE facilitate the conversion of the lipoplex lamellar phase (L_α) into the non-lamellar inverted hexagonal (H_{II}) and cubic phases which play an important role in membrane fusion.[37, 38] In early and elegant siRNA SNALP delivery studies, MacLachlan and co-workers reported the importance of the saturation of C=C along the lipids chains.[39] They found that, in an series of symmetrical 1,2-dialkyloxy-*N*,*N*-dimethyl-3-aminopropane analogues, as C=C saturation increased, lamellar phase (L_α) to non-lamellar inverted hexagonal (H_{II}) phase transition temperatures increased, an indicator of decreasing fusogenicity, and that less fusogenic particles are more readily internalized by cells, but with lower gene silencing efficiency. They also argued that as electrostatic binding is a precursor to uptake, the pK_a values of the cationic lipid will be important. Their results support an siRNA transfection model in which endosomal release, mediated by fusion with the endosomal membrane, results in cytoplasmic translocation of the siRNA payload.[39] Whilst fully agreeing with their argument, in addition to our two (different) unsaturated acyl chains (18:2 and 18:1), we also have incorporated cholesterol, a known membrane fusogen[38] in our efficient formulations.

Lipoplexes containing LinOS/DOPE showed enhanced gene silencing (Figure 5) compared to LinOS lipoplex formulations lacking any helper lipid. However, LinOS/DOPE lipoplexes showed less siEGFP-AF delivery (Figure 4) when compared to LinOS/Chol lipoplexes. Lipoplexes containing cholesterol have also been found to be more effective in vivo than those containing DOPE.[40-44] The particle size of LinOS/Chol lipoplexes that resulted in the best balance between gene silencing and siEGFP-AF delivery were measured (Table 1). These LinOS/Chol lipoplexes were much smaller than the LinOS/DOPE lipoplexes (Table 1). DOPE containing lipoplexes showed immediate loss of integrity in the presence of serum which might explain the higher efficiency of

cholesterol containing lipoplexes in vivo.[44] Thus, lipoplexes of LinOS/Chol at 1:2 ratio resulted in the best siEGFP-AF delivery and gene silencing. Further investigation with respect to the effect of decreasing the amount of complexed siRNA from 15 pmol to 3.75 pmol at LinOS/Chol 1:2 ratio showed the amount of siEGFP-AF delivered was down to 20-33% (5-fold-3-fold). The symmetrical spermine conjugate DOS, which we have demonstrated forms siRNA lipoplexes that efficiently silence EGFP,[20] was chosen to prepare lipoplexes with the DOS/Chol ratio of 1:2, experimentally determined to be the best for LinOS/Chol, to investigate the effect of changing the cationic lipid on the siEGFP-AF delivery and EGFP knock-down. Figure 6 shows that both LinOS and DOS mixtures with cholesterol markedly increased siEGFP-AF delivery, with LinOS/Chol lipoplexes resulting in more enhanced siEGFP-AF delivery. The data in Figure 7 show that the reduction of EGFP expression was essentially the same at both siEGFP-AF concentrations used and for both formulae. Although lipoplexes prepared with 3.75 pmol siEGFP-AF have a lower amount of siRNA, they therefore have a higher N/P charge ratio, $N/P = 11.9$ compared with $N/P = 3.0$ for lipoplexes prepared with 15 pmol siEGFP-AF, which may play a role in the interactions with cell membranes, hence promoting gene silencing. The differences seen between lipoplexes of LinOS/Chol and DOS/Chol (Figures 6 and 7) can be attributed to the difference between the fatty acids in LinOS and DOS. LinOS contains one oleoyl chain (18:1, one double bond), and one linoleoyl (18:2, two double bonds) while DOS contains two oleoyl chains. The differences in the hydrophobic volume of these cationic lipids will affect the transfection efficiency of lipoplexes,[45-47] and LinOS lipoplexes were better than DOS in EGFP silencing in HeLa cells (Figure 7). Figures 6 and 7 also show that lipoplexes prepared with scrambled siNC-AF did not result in any significant gene silencing, therefore the reduction in EGFP expression on transfection with siEGFP-AF lipoplexes is due to sequence specific gene silencing, and not due to any off target or lipid related effects e.g. toxicity. The alamarBlue cell viability assay data (Figure 12) show that the lipoplexes were particularly well tolerated by HeLa cells with viabilities ≥ 81%. The best viability (94%) for lipoplexes containing cholesterol was achieved using LinOS/Chol 1:2 with 0.375 pmol siRNA. Such low toxicity (remarkably high cell viability), at the N/P ratios used, bodes well for future in vivo studies.

The new cationic lipid LinOS was characterized and evaluated for its ability to deliver siRNA to HeLa cells, and for its effect on gene silencing efficiency. LinOS was used to prepare self-assembled lipoplexes with siRNA, either alone, or in a co-formula with cholesterol or DOPE at various ratios of the cationic lipid/helper lipid. The lipoplexes co-formulated with cholesterol resulted in particle size that is smaller than the particle size of lipoplexes co-formulated with DOPE. The lipoplexes co-formulated with either cholesterol or DOPE were superior to those without cholesterol in terms of efficiency of siRNA delivery, with the lipoplexes having LinOS/Chol ratio 1:2 resulting in the highest delivery. These lipoplexes resulted in better gene silencing than the lipoplexes of LinOS, and in a comparable manner to the commercial transfecting agent TransIT-TKO in the presence of 10%

FCS in the HeLa cell culture media. The prepared lipoplexes resulted in cell viability that is higher than 80% in HeLa cells. These results show that LinOS/Chol mixtures can form self-assembled lipoplexes with siRNA, and are promising non-toxic non-viral vectors for siRNA.

ACKNOWLEDGEMENTS

ABBREVIATIONS USED

DMEM, Dulbecco's Modified Eagle's Medium;

DOS, N^4,N^9-dioleoyl-1,12-diamino-4,9-diazadodecane;

EGFP, enhanced green fluorescent protein;

FCS, fetal calf serum;

HRMS, high-resolution mass spectrometry;

LinOS, N^4-linoleoyl-N^9-oleoyl-1,12-diamino-4,9-diazadodecane;

WGA, wheat germ agglutinin

References

1. Blagbrough, I. S.; Zara, C. Animal models for target diseases in gene therapy - using DNA and siRNA delivery strategies. *Pharm. Res.* **2009**, *26*, 1-18.
2. Fire, A.; Xu, S. Q.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. *Nature* **1998**, *391*, 806-811.
3. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **2001**, *411*, 494-498.
4. Gaynor, J. W.; Campbell, B. J.; Cosstick, R. RNA interference: a chemist's perspective. *Chem. Soc. Rev.* **2010**, *39*, 4169-4184.
5. Watts, J. K.; Deleavey, G. F.; Damha, M. J. Chemically modified siRNA: tools and applications. *Drug Discov. Today* **2008**, *13*, 842-855.
6. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery. *Nat. Rev. Drug Discov.* **2009**, *8*, 129-138.
7. Lu, J. J.; Langer, R.; Chen, J. Z. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. *Mol. Pharmaceutics* **2009**, *6*, 763-771.

8. Patil, M. L.; Zhang, M.; Taratula, O.; Garbuzenko, O. B.; He, H.; Minko, T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. *Biomacromolecules* **2009**, *10*, 258-266.

9. Mintzer, M. A.; Simanek, E. E. Nonviral vectors for gene delivery. *Chem. Rev.* **2009**, *109*, 259-302.

10. Wang, J.; Lu, Z.; Wientjes, M. G.; Au, J. L. S. Delivery of siRNA Therapeutics: Barriers and Carriers. *AAPS J.* **2010**, *12*, 492-503.

11. Yuan, X.; Naguib, S.; Wu, Z. Recent advances of siRNA delivery by nanoparticles. *Expert Opin. Drug Deliv.* **2011**, *8*, 521-536.

12. Blagbrough, I. S.; Ghonaim, H. M., Polyamines and their conjugates for gene and siRNA delivery. In *Biological aspects of biogenic amines, polyamines and conjugates*, Dandrifosse, G., Eds.; Research Signpost: India, 2009; Vol. pp 81-112.

13. Tseng, Y.-C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. *Adv. Drug Deliv. Rev.* **2009**, *61*, 721-731.

14. Stanton, M. G.; Colletti, S. L. Medicinal chemistry of siRNA delivery. *J. Med. Chem.* **2010**, *53*, 7887-7901.

15. Schroeder, A.; Levins, C. G.; Cortez, C.; Langer, R.; Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. *J Intern Med.* **2010**, *267*, 9-21.

16. Soltan, M. K.; Ghonaim, H. M.; El Sadek, M.; Abou Kull, M.; El-Aziz, L. A.; Blagbrough, I. S. Design and synthesis of N^4,N^9-disubstituted spermines for non-viral siRNA delivery - Structure-activity relationship studies of siFection efficiency versus toxicity. *Pharm. Res.* **2009**, *26*, 286-295.

17. Ghonaim, H. M.; Li, S.; Blagbrough, I. S. N^1,N^{12}-Diacyl spermines: SAR studies on non-viral lipopolyamine vectors for plasmid DNA and siRNA formulation. *Pharm. Res.* **2010**, *27*, 17-29.

18. Ghonaim, H. M.; Li, S.; Blagbrough, I. S. Very long chain N^4,N^9-diacyl spermines: Non-viral lipopolyamine vectors for efficient plasmid DNA and siRNA delivery. *Pharm. Res.* **2009**, *26*, 19-31.

19. McLaggan, D.; Adjimatera, N.; Sepcic, K.; Jaspars, M.; MacEwan, D. J.; Blagbrough, I. S.; Scott, R. H. Pore forming polyalkylpyridinium salts from marine sponges versus synthetic lipofection systems: distinct tools for intracellular delivery of cDNA and siRNA. *BMC Biotech.* **2006**, *6*.

20. Metwally, A. A.; Pourzand, C.; Blagbrough, I. S. Efficient gene silencing by self-assembled complexes of siRNA and symmetrical fatty acid amides of spermine. *Pharmaceutics* **2011**, *3*, 125-140.

21. Ahmed, O. A. A.; Pourzand, C.; Blagbrough, I. S. Varying the unsaturation in N^4,N^9-dioctadecanoyl spermines: Nonviral lipopolyamine vectors for more efficient plasmid DNA formulation. *Pharm. Res.* **2006**, *23*, 31-40.

22. Ghonaim, H. M.; Ahmed, O. A. A.; Pourzand, C.; Blagbrough, I. S. Varying the chain length in N^4,N^9-diacyl spermines: Non-viral lipopolyamine vectors for efficient plasmid DNA formulation. *Mol. Pharmaceutics* **2008**, *5*, 1111-1121.

23. Metwally, A. A.; Blagbrough, I. S. Self-assembled lipoplexes of short interfering RNA (siRNA) Using spermine-based fatty acid amide guanidines: effect on gene silencing efficiency. *Pharmaceutics* **2011**, *3*, 406-424.

24. Blagbrough, I. S.; Metwally, A. A.; Ghonaim, H. M. Asymmetrical N^4,N^9-diacyl spermines: SAR studies of nonviral lipopolyamine vectors for efficient siRNA delivery with silencing of EGFP reporter gene. *Mol. Pharmaceutics* **2012**, *9*, 1853-1861.

25. Metwally, A. A.; Reelfs, O.; Pourzand, C.; Blagbrough, I. S. Efficient silencing of EGFP reporter gene with siRNA delivered by asymmetrical N^4,N^9-diacyl spermines. *Mol. Pharmaceutics* **2012**, *9*, 1862-1876.

26. Kremer, J. M. H.; Esker, M. W. J.; Pathmamanoharan, C.; Wiersema, P. H. Vesicles of variable diameter prepared by a modified injection method. *Biochemistry* **1977**, *16*, 3932-3935.

27. Bakht, O.; Pathak, P.; London, E. Effect of the structure of lipids favoring disordered domain formation on the stability of cholesterol-containing ordered domains (lipid rafts): Identification of multiple raft-stabilization mechanisms. *Biophys. J.* **2007**, *93*, 4307-4318.

28. Ross, P. C.; Hui, S. W. Lipoplex size is a major determinant of in vitro lipofection efficiency. *Gene Ther.* **1999**, *6*, 651-659.

29. Han, S. E.; Kang, H.; Shim, G. Y.; Suh, M. S.; Kim, S. J.; Kim, J. S.; Oh, Y. K. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. *Int. J. Pharm.* **2008**, *353*, 260-269.

30. Marchini, C.; Montani, M.; Amici, A.; Amenitsch, H.; Marianecci, C.; Pozzi, D.; Caracciolo, G. Structural stability and increase in size rationalize the efficiency of lipoplexes in serum. *Langmuir* **2009**, *25*, 3013-3021.

31. Hoekstra, D.; Rejman, J.; Wasungu, L.; Shi, F.; Zuhorn, I. Gene delivery by cationic lipids: in and out of an endosome. *Biochem. Soc. Trans.* **2007**, *35*, 68-71.

32. Ming, X.; Sato, K.; Juliano, R. L. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. *J. Control. Release* **2011**, *153*, 83-92.

33. Desigaux, L.; Sainlos, M.; Lambert, O.; Chevre, R.; Letrou-Bonneval, E.; Vigneron, J. P.; Lehn, P.; Lehn, J. M.; Pitard, B. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 16534-16539.

34. Wasungu, L.; Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. *J. Control. Release* **2006**, *116*, 255-264.

35. Xu, L.; Anchordoquy, T. J. Cholesterol domains in cationic lipid/DNA complexes improve transfection. *Biochim. Biophys. Acta. Biomembr.* **2008**, *1778*, 2177-2181.

36. Xu, L.; Anchordoquy, T. J. Effect of Cholesterol Nanodomains on the Targeting of Lipid-Based Gene Delivery in Cultured Cells. *Mol. Pharmaceutics* **2010**, *7*, 1311-1317.

37. Margineanu, A.; De Feyter, S.; Melnikov, S.; Marchand, D.; van Aerschot, A.; Herdewijn, P.; Habuchi, S.; De Schryver, F. C.; Hofkens, J. Complexation of lipofectarnine and cholesterol-modified DNA sequences-studied by single-molecule fluorescence techniques. *Biomacromolecules* **2007**, *8*, 3382-3392.

38. Tenchov, B. G.; MacDonald, R. C.; Siegel, D. P. Cubic phases in phosphatidylcholine-cholesterol mixtures: Cholesterol as membrane fusogen *Biophys. J.* **2006**, *91*, 2508-2516.

39. Heyes, J.; Palmer, L.; Bremner, K.; MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. *J. Control. Release* **2005**, *107*, 276-287.

40. Li, S.; Tseng, W. C.; Stolz, D. B.; Wu, S. P.; Watkins, S. C.; Huang, L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: Implications for intravenous lipofection. *Gene Ther.* **1999**, *6*, 585-594.

41. Hirsch-Lerner, D.; Zhang, M.; Eliyahu, H.; Ferrari, M. E.; Wheeler, C. J.; Barenholz, Y. Effect of "helper lipid" on lipoplex electrostatics. *Biochim. Biophys. Acta Biomembr.* **2005**, *1714*, 71-84.

42. Templeton, N. S.; Lasic, D. D.; Frederik, P. M.; Strey, H. H.; Roberts, D. D.; Pavlakis, G. N. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. *Nat. Biotechnol.* **1997**, *15*, 647-652.

43. Sternberg, B.; Hong, K. L.; Zheng, W. W.; Papahadjopoulos, D. Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. *Biochim. Biophys. Acta Biomembr.* **1998**, *1375*, 23-35.

44. Simberg, D.; Weisman, S.; Talmon, Y.; Faerman, A.; Shoshani, T.; Barenholz, Y. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. *J. Biol. Chem.* **2003**, *278*, 39858-39865.

45. Balasubramaniam, R. P.; Bennett, M. J.; Aberle, A. M.; Malone, J. G.; Nantz, M. H.; Malone, R. W. Structural and functional analysis of cationic transfection lipids: The hydrophobic domain. *Gene Ther.* **1996**, *3*, 163-172.

46. Koynova, R.; Tenchov, B.; Wang, L.; MacDonald, R. C. Hydrophobic moiety of cationic lipids strongly modulates their transfection activity. *Mol. Pharmaceutics* **2009**, *6*, 951-958.

47. Nantz, M. H.; Dicus, C. W.; Hilliard, B.; Yellayi, S.; Zou, S. M.; Hecker, J. G. The benefit of hydrophobic domain asymmetry on the efficacy of transfection as measured by in vivo imaging. *Mol. Pharmaceutics* **2010**, *7*, 786-794.